Hepatocellular carcinoma, colorectal liver metastasis, liver function
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: In order to be eligible to participate in this study, a participant must meet all of the following criteria:18 years or olderSigned informed consent obtained prior to any study-specific procedurePatient diagnosed with one or more liver lesions who are scheduled for a HBS scan prior to a major hepatectomy. Origin of liver lesion can be: Primary hepatocellular carcinoma Hilar (Klatskin), intrahepatic or perihilar cholangiocarcinomaColorectal liver metastases
Exclusion criteria
Exclusion criteria: A potential participant who meets any of the following criteria will be excluded from participation in this study:Age <18 yearsNot able to sign informed consentGeneral contraindications for MRIChronic renal insufficiency or eGFR < 30 ml/min/1.73 m2Known or family history of congenital prolonged QT-syndromePrior history of arrhythmia after the use of cardiac repolarisation time prolonging drugsPrior history of allergic reaction to gadolinium-containing compoundsPrior history of asthma bronchiale
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study parameter is the liver function measured with DCE MRI. This DCE MRI liver function will be compared to the liver function measured with HBS (the reference standard). | — |
Secondary
| Measure | Time frame |
|---|---|
| The parameters calculated from all MP-qMRI scans will be correlated to the degree of steatosis, inflammation and fibrosis present in the resected non-tumorous liver. The following MP-qMRI parameters will be considered:Fat fraction measured with PDFFDiffusion and perfusion fraction measured with IVIM MRIStiffness and viscosity measured with MRET2* and T1 relaxivityThe MP-qMRI parameters mentioned in the previous point, will also be correlated to the liver function measured with HBS. The MP-qMRI parameters prior to the liver augmentation procedure will be compared to the parameters after the liver augmentation procedure. The change in liver function measured with MP-qMRI will be compared to the change in liver function measured with HBS. | — |
Countries
Netherlands
Contacts
Amsterdam UMC